PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 201 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2015. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $828,000 | -89.4% | 14,000 | -78.5% | 0.24% | -85.2% |
| Q3 2017 | $7,784,000 | -40.6% | 65,000 | -56.7% | 1.65% | -39.3% |
| Q2 2017 | $13,110,000 | +56.6% | 150,000 | -33.3% | 2.72% | +74.7% |
| Q1 2017 | $8,370,000 | +36.3% | 225,000 | +12.5% | 1.56% | +5.5% |
| Q4 2016 | $6,140,000 | -39.0% | 200,000 | +33.3% | 1.48% | -9.4% |
| Q3 2016 | $10,058,000 | +1952.7% | 150,000 | +2207.7% | 1.63% | +638.0% |
| Q3 2015 | $490,000 | -76.0% | 6,500 | -62.9% | 0.22% | -66.6% |
| Q2 2015 | $2,043,000 | -85.6% | 17,500 | -70.8% | 0.66% | -74.0% |
| Q1 2015 | $14,166,000 | +149.5% | 60,000 | +100.0% | 2.55% | -6.5% |
| Q4 2014 | $5,678,000 | +375.9% | 30,000 | +500.0% | 2.72% | +320.5% |
| Q3 2014 | $1,193,000 | +1707.6% | 5,000 | +400.0% | 0.65% | +1278.7% |
| Q2 2014 | $66,000 | -94.4% | 1,000 | -91.2% | 0.05% | -93.3% |
| Q1 2014 | $1,180,000 | -54.4% | 11,330 | -54.7% | 0.70% | -56.0% |
| Q4 2013 | $2,588,000 | – | 25,000 | – | 1.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 2,536,156 | $21,405,000 | 2.24% |
| Palo Alto Investors LP | 1,396,163 | $11,784,000 | 0.99% |
| Camber Capital Management LP | 1,950,000 | $16,458,000 | 0.98% |
| TANG CAPITAL MANAGEMENT LLC | 800,000 | $6,752,000 | 0.95% |
| Capital Impact Advisors, LLC | 147,303 | $1,243,000 | 0.52% |
| Sofinnova Investments, Inc. | 638,026 | $5,385,000 | 0.50% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 963,212 | $8,130,000 | 0.26% |
| RICE HALL JAMES & ASSOCIATES, LLC | 466,482 | $3,937,000 | 0.22% |
| PDT Partners, LLC | 204,238 | $1,724,000 | 0.14% |
| Eversept Partners, LP | 58,251 | $491,638 | 0.12% |